This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Jim Silverman

Contributor

Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.

Jim Silverman
By This Author:
« Back
Page 1 of 1
Next »

Ariad Pharma: The Contrarian Long Thesis

By Jim Silverman

Iclusig may find use in other cancers and '113 is better than the market believes.

11:00AM 10/24/13

Cell Therapeutics: Addicted to Reverse Stock Splits

By Jim Silverman

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

10:00AM 04/18/13

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

By Jim Silverman

Instead of selling stock whenever the wind blows, biotech execs should be buying.

08:00AM 01/24/13

Genta: 1998-2012

By Jim Silverman

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

07:00AM 10/25/12

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

By Jim Silverman

How best to invest in the next important clinical trial catalyst facing Celgene.

08:07AM 09/25/12

« Back
Page 1 of 1
Next »

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,964.88 -118.92 -0.70%
S&P 500 1,982.66 -5.32 -0.27%
NASDAQ 4,457.6270 -14.4810 -0.32%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs